Diagnosis and Risk Stratification

For patients at risk of plasma cell disorders, early identification is critical to ensure better outcomes. Coined as MASS-FIX, our innovative approach uses matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS), and marks the first major breakthrough in multiple myeloma screening since electrophoresis was developed in 1967.

An algorithmic approach
to guide diagnosis

Our updated approach to Flourescent In-Situ Hybridization (FISH) testing takes into account the fact that multiple myeloma is increasingly recoginized as more than one disease with cytogenic, molecular, and proliferative heterogenity. While novel agents and combinations are rapidly redefining the treatment paradigm, patient outcomes vary based on risk stratification.

Created in conjunction with Mayo Clinic’s Multiple Myeloma Clinican Practice, mSMART uses flow cytomtery, FISH, and the latest consensus to determine a patient’s genetic risk of developing multiple myeloma to better inform individualized treatment plans and provides clinicians with a comprehensive and correlated patient profile.

Which test should I order?

A Test in Focus

Linda Baughn Ph.D. gives an overview of the Plasma Cell Proliferative Disorder FISH test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered and what clinical action can be taken due to the results provided.

mSMART: Stratificationfor myeloma and risk-adapted therapy

The group's mission is to present the state-of -the-art approach to management of these plasma cells disorders including Myeloma, Amyloidosis, and Waldenstrom's Macroglobulinemia. Views expressed here are opinions of a group of experts, based on best available evidence.